ArticleACS omega2026
A Compound-Centric Framework for Mapping Plant Chemical Space through Structural Scaffolds and Bioactivity Evidence.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Open repositories have greatly expanded access to plant chemical occurrence data at scale, yet their direct use in compound prioritization remains limited by taxonomic inconsistency, structural redundancy, and uneven bioactivity annotation. Here, we present a compound-centric framework that transforms literature-curated occurrence records into interpretable, evidence-aware outputs by integrating LOTUS species-structure associations, World Flora Online taxonomic reconciliation, InChIKey-based dereplication, Murcko scaffold analysis, and conservative ChEMBL-linked bioactivity evidence. Applied to Phyllanthaceae as a case study, the workflow organizes reported chemical space across genera, resolves structure-level redundancy, and links scaffold-level novelty to family-level rarity and indexed activity records. This strategy distinguishes two complementary evidence-aware categories: lineage-restricted compounds with ChEMBL-linked activity records (STARS) and lineage-restricted compounds lacking qualifying ChEMBL activity records (HIDDEN GEMS). More broadly, the taxon-flexible design supports analyses across multiple taxonomic scales in plant lineages represented in LOTUS. It provides an auditable framework for converting heterogeneous occurrence data into transparent outputs that support evidence-aware prioritization in natural products research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.